SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001213900-24-073934
Filing Date
2024-08-29
Accepted
2024-08-29 16:48:33
Documents
64
Period of Report
2024-06-30

Document Format Files

Seq Description Document Type Size
1 QUARTERLY REPORT ea0212615-10q_silexion.htm   iXBRL 10-Q 978565
2 CERTIFICATION ea021261501ex31-1_silexion.htm EX-31.1 8078
3 CERTIFICATION ea021261501ex31-2_silexion.htm EX-31.2 8093
4 CERTIFICATION ea021261501ex32-1_silexion.htm EX-32.1 4548
5 CERTIFICATION ea021261501ex32-2_silexion.htm EX-32.2 4484
  Complete submission text file 0001213900-24-073934.txt   4692406

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE slxn-20240630.xsd EX-101.SCH 46574
7 XBRL CALCULATION FILE slxn-20240630_cal.xml EX-101.CAL 36704
8 XBRL DEFINITION FILE slxn-20240630_def.xml EX-101.DEF 218176
9 XBRL LABEL FILE slxn-20240630_lab.xml EX-101.LAB 369340
10 XBRL PRESENTATION FILE slxn-20240630_pre.xml EX-101.PRE 218547
67 EXTRACTED XBRL INSTANCE DOCUMENT ea0212615-10q_silexion_htm.xml XML 501795
Mailing Address 2 HAMAYAN STREET MODIIN-MACCABIM-REUT L3 7177871
Business Address 2 HAMAYAN STREET MODIIN-MACCABIM-REUT L3 7177871 972-8-6286005
Silexion Therapeutics Corp (Filer) CIK: 0002022416 (see all company filings)

IRS No.: 000000000 | State of Incorp.: E9 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-42253 | Film No.: 241264434
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)